Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
37 hedge funds and large institutions have $14.2M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 17 reducing their positions, and 16 closing their positions.
23% less funds holding
Funds holding: 48 → 37 (-11)
47% less capital invested
Capital invested by funds: $26.8M → $14.2M (-$12.6M)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
82% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 17
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$319K |
| 2 |
E
Ergoteles
New York
|
+$74K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$48.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$670K |
| 2 |
State Street
Boston,
Massachusetts
|
-$265K |
| 3 |
JP Morgan Chase
New York
|
-$148K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$130K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$96.4K |
SGTX Hedge Fund Activity: Q2 2022 in Review
37 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q2 2022, worth a combined $14.2M — down 47% from $26.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SGTX and 6 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $319K. The largest seller was BlackRock, cutting an estimated $670K.
- 37 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q2 2022, down from 48 in Q1 2022.
- Funds reported $14.2M of Sigilon Therapeutics, Inc. Common Stock stock for Q2 2022, down 47% quarter-over-quarter.
- 6 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q2 2022 and 16 closed out, a net change of -10 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q2 2022 was Millennium Management, an estimated $319K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $670K sold.
Based on aggregated 13F filings for Q2 2022.